-
Mashup Score: 1EMERALD-1: Durvalumab Plus Bevacizumab With TACE Versus TACE Monotherapy | Docwire News - 4 month(s) ago
Dr. Riccardo Lencioni presented new data from the EMERALD-1 study on combining TACE plus durvalumab with and without bevacizumab.
Source: www.docwirenews.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 2
Dr. Christopher Lieu gives an overview of some of the top presentations and data to look out for at ASCO GI 2024, and discusses the importance of the event.
Source: www.docwirenews.comCategories: Expert PicksTweet
-
Mashup Score: 2
Dr. Christopher Lieu gives an overview of some of the top presentations and data to look out for at ASCO GI 2024, and discusses the importance of the event.
Source: www.docwirenews.comCategories: Expert PicksTweet
-
Mashup Score: 9
Drs. Hossein Borghaei and Tony Calles join Dr. Nabhan to dissect cutting-edge data from the ESMO Congress 2023, spotlighting the transformative landscape of lung cancer treatment.
Source: www.docwirenews.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0CRAFITY Score Aids in Prognosis of HCC Patients Undergoing Immunotherapy, TACE | Docwire News - 4 month(s) ago
The CRAFITY score can provide equal prognostic benefits for patients with HCC undergoing transarterial chemoembolization combined with PD-L1 inhibitors and MTT.
Source: www.docwirenews.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 0Atezolizumab Plus Bevacizumab Similar to Lenvatinib in Elder Patients With HCC | Docwire News - 4 month(s) ago
Atezolizumab plus bevacizumab provides similar efficacy as lenvatinib in patients with HCC aged 80 years or older, and may serve as a first-line treatment.
Source: www.docwirenews.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 0Is Sintilimab Effective for Patients With Unresectable Gastric, Gastroesophageal Junction Cancers? | Docwire News - 4 month(s) ago
Researchers sought to determine if a combination of sintilimab and first-line chemotherapy would improve survival rates.
Source: www.docwirenews.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 0Does Salvage Hepatectomy Benefit Patients With Unresectable HCC, cCR After Conversion Therapy? | Docwire News - 4 month(s) ago
Researchers compared the data of patients who underwent salvage hepatectomy and those who received nonsurgical treatment.
Source: www.docwirenews.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 0
A research team examined the efficacy of several targeted agents as second-line treatments for advanced gastric cancer through the K-Umbrella study.
Source: www.docwirenews.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 0Efficacy of Pembrolizumab Plus Lenvatinib for Patients With Advanced HCC | Docwire News - 4 month(s) ago
Researchers compared the combination therapy with lenvatinib alone.
Source: www.docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
A phase 3, double-blind study compared the efficacy of #pembrolizumab plus #lenvatinib with lenvatinib alone and found that the combination therapy did not significantly improve OS and PFS in patients with advanced hepatocellular carcinoma. Learn more: https://t.co/MmEyfsaC5v https://t.co/eyHlJz0q3T
-
RT @GiOncNow: EMERALD-1 study results are being presented at @ASCO #GI24 now. Read the results: https://t.co/9wdq6lfk7g